AstraZeneca's Rare Drug Trial Failure Sends Shares Plunging

AstraZeneca Plc's shares dropped more than 10% after a trial of a new heart drug failed to help prevent heart problems in patients with a rare disease. Bloomberg Intelligence's Sam Fazeli has more on "Bloomberg Open Interest." (Source: Bloomberg)

You are being sent to the original publisher. FX Radar keeps this reference for market context and source discovery.